Table 2.

Responses to CAR T-cell therapy and survival

	Total (N = 87)	Axi-cel (n = 50)	Liso-cel (n = 37)
Median follow-up (95% CI), mo	11 (10-14)	12 (10-18)	10 (9-14)
Best response
CR	68% (57-77)	72% (58-84)	62% (45-78)
PR	21% (13-31)	20% (10-34)	22% (10-38)
1-mo response
CR	54% (43-65)	62% (47-75)	43% (27-61)
PR	28% (19-38)	26% (15-40)	30% (16-47)
PFS, median (95% CI)	NR (9 to NR)	NR (9 to NR)	11 (6 to NR)
12-mo PFS	53%, (42-66)	59% (45-76)	44% (29-68)
DOR, median (95% CI)	NR (11 to NR)	NR (11 to NR)	NR (9 to NR)
12-mo DOR	61% (49-76)	62% (48-81)	59% (41-86)
OS, median (95% CI)	NR (NR to NR)	NR (NR to NR)	NR (NR to NR)
12-mo OS	74% (64-86)	77% (65-92)	71% (55-91)

Values are presented as rate (95% CI) unless otherwise stated.

NR, not reached.